Gulf War Illness Inflammation Reduction Trial

Chronic Pain Clinical Trial

— GWIIRT  

Official title:

Gulf War Illness Inflammation Reduction Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02506192
• Other study ID #: 4554-A
• Status: Completed
• Phase: Phase 2
• Start date: July 2015
• Est. completion date: October 19, 2023

Study information

• Verified date: November 2023
• Source: Minneapolis Veterans Affairs Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this clinical trial is to determine if treatment with an anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change from baseline of HRQOL with respect to physical functioning and symptoms. Secondary outcomes measures include changes from baseline levels of GWI-associated biomarkers of inflammation in peripheral blood, GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and HRQOL with respect to mental functioning.

Description:

During Desert Shield and Desert Storm (Aug 2, 1990 to July 31,1991) 696,841 United States Military personnel were deployed to the Kuwaiti Theater of Operations. Today approximately one-third of those veterans are suffering from GWI, an unexplained chronic multi-symptom illness. Evidence of chronic inflammation in veterans with GWI has emerged from previous observational studies. The goal of this trial is to determine if reducing the GWI-associated chronic inflammation is an effective treatment for GWI. This is a randomized, two group, placebo controlled, double blind clinical trial. The treatment group will receive a low dose (2x5mg) once a day of delayed-release prednisone (Rayos) for 8 weeks. The placebo group will receive matching placebo (2x5mg) once a day for 8 weeks. The primary outcome measure for this clinical trial is a change from baseline of HRQOL with respect to physical functioning and symptoms. The secondary outcome measures include changes from baseline of peripheral blood levels of GWI-associated biomarkers of inflammation, changes from baseline of GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and a change from baseline of HRQOL with respect to mental functioning.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: October 19, 2023
• Est. primary completion date: October 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Scores moderate-severe on at least 3 out of 6 domains from the Kansas GWI Case Definition

• Deployed, (and honorably discharged), from the Kuwaiti Theater of Operation (August 2, 1990-July 31, 1991)

Exclusion Criteria:

• Hospitalization anytime since 1990 for Alcohol or Drug Dependence, Depression, or PTSD

• Known hypersensitivity to Prednisone

• Liver, (active or recent Hepatitis B or C treatment with a completion date within the past 6 months, or alcohol liver disease), or Kidney Disease (Hep B and C ok if after 6 months of treatment)

• Treated Diabetes

• Females who are Pregnant or Nursing

• Female who refuses to use an accepted method of birth control

• Exclusionary Labs: C-Reactive Protein >25, Creatinine Clearance <30, EFGR = 30, Hgb A1-C >7, Glucose >120, WBC >12, RBC >6.2, Hematocrit >60, Hemoglobin <11, Platelets <100, Liver Function Tests (2 x the upper limit of AST and ALT, 2 x the upper limit of Total Bilirubin, and Alkaline Phosphatase)

• Has Inflammatory Arthritis (RA, or Psoriatic Arthritis, Spondylitis, Polyarthritis)

• Reactive Arthritis, or IBD associated Arthritis

• Has any major inflammatory disease (acute Chronic Infections, Ulcerative Colitis, Crohn's Disease, Inflammatory lung diseases- COPD or Asthma requiring steroid treatment, Pericarditis, Vasculitis)

• Has an chronic/active infection

• Chronic use of Prednisone or Corticosteroids (occasional inhaled use of steroids acceptable)

• Active Gum Disease or Dental Infection

• Has been diagnosed with Lupus, Stroke, or Multiple Sclerosis. or any other diagnosis that produces symptoms of fatigue, cognitive impairment, or pain will be excluded based on the Kansas GWI Case definition

• Has a condition that may interfere with the ability to accurately report symptoms, (Severe Psychiatric Problems, Schizophrenia, Bipolar Disorder, Alcohol or Drug Dependence requiring hospitalization, or regular illegal drug use)

• Heart Disease (other than Hypertension), Heart Failure or Coronary Heart Disease requiring hospitalization within the past 12 months

• Cancer (other than basal cell skin cancer), requiring treatment within the past 12 months, or life expectancy of less than 1 year.

• Hospitalization within the past 3 months

Related Conditions & MeSH terms

• Chronic Inflammation
• Chronic Pain
• Cognitive Impairment
• Fatigue
• Inflammation

Intervention

Drug:
• Modified-Release Prednisone
Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
• Placebo
Placebo oral tablets (2x5mg) daily for 8 weeks

Locations

Country	Name	City	State
United States	Minneapolis Veterans Affairs Medical Center	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Minneapolis Veterans Affairs Medical Center	United States Department of Defense

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bach RR, Rudquist RR. Gulf war illness inflammation reduction trial: A phase 2 randomized controlled trial of low-dose prednisone chronotherapy, effects on health-related quality of life. PLoS One. 2023 Jun 15;18(6):e0286817. doi: 10.1371/journal.pone.0286817. eCollection 2023. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS) Scores at 8 and 16 Weeks	The SF-36V is a modification of the well-established Medical Outcomes Study Short Form Health Survey (SF-36). It surveys eight concepts of health: physical functioning, role limitations because of physical problems, bodily pain, general health perceptions, energy/vitality, social functioning, role limitations due to emotional problems and mental health. From these concepts, two summary component scores are derived: a Physical Component Summary (PCS) and a Mental Component Summary (MCS).; To calculate PCS, scales are standardized with a scoring algorithm or by the scoring software. Scores are standardized and range from 0 to 100, with a US population mean of 50 points and a SD of 10 points. The PCS and the MCS have been demonstrated to have excellent psychometric properties. SF-36V PCS is a measure of HRQOL with respect to physical functioning and symptoms. Higher scores indicate better health status,	0, 8, and 16 weeks
Secondary	Change From Baseline of McGill Pain Questionnaire-short Form (MPQ) Scores at 8 and 16 Weeks	MPQ asks questions about sensory pain, affective pain, pain now, and typical pain	0, 8, and 16 weeks
Secondary	Change From Baseline of Multidimensional Fatigue Inventory (MFI) Scores at 8 and 16 Weeks	MFI asks questions about general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue.	0, 8, and 16 weeks
Secondary	Change From Baseline of Cognitive Failures Questionnaire (CFQ) Scores at 8 and 16 Weeks	CFQ asks questions about cognitive symptoms such as attention, concentration, and memory	0, 8, and 16 weeks
Secondary	Change From Baseline of Veterans RAND 36-Item Health Survey Mental Component Summary Score (MCS) Scores at 8 and 16 Weeks	SF-36V MCS is a measure of HRQOL with respect to mental functioning. The SF-36V is a modification of the well-established Medical Outcomes Study Short Form Health Survey (SF-36). It surveys eight concepts of health: physical functioning, role limitations because of physical problems, bodily pain, general health perceptions, energy/vitality, social functioning, role limitations due to emotional problems and mental health. From these concepts, two summary component scores are derived: a Physical Component Summary (PCS) and a Mental Component Summary (MCS).; To calculate MCS, scales are standardized with a scoring algorithm or by the scoring software. Scores are standardized and range from 0 to 100, with a US population mean of 50 points and a SD of 10 points. The PCS and the MCS have been demonstrated to have excellent psychometric properties. SF-36V MCS is a measure of HRQOL with respect to mental functioning and symptoms. Higher scores indicate better health status,	0, 8, and 16 weeks
Secondary	Change From Baseline of Gulf War Illness-associated Peripheral Blood Biomarkers	Peripheral blood biomarker levels are quantified by multi-analyte profiling (MAP) and complete blood count (CBC) analyses	0, 8, and 16 weeks

External Links

•   link to citation